| Primary | Percentage of Participants With Adverse Drug Reactions | Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | percentage of participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Number of Adverse Drug Reactions | Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.. | Posted | | Number | | number of adverse drug reaction | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Gender | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Pregnancy | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All female participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Age | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Inpatient/Outpatient | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Previous Treatment of Human Immunodeficiency Virus (HIV)-Infection | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Races | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Route of Infection | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Disease Duration | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Past Medical History | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Allergy | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Diseases | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Renal Disorder | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Liver Disorder | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Haemophilia | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Haemophilia With/Without Hepatitis C | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Center for Disease Control (CDC) Classification Category of Severity Before Treatment | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Administration Method of Lopinavir/Ritonavir | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Mean Daily Dose of Lopinavir/Ritonavir | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Use Duration of Lopinavir/Ritonavir | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Anti-HIV Concomitant Drugs | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Anti-HIV Concomitant Non-Drug Treatments | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Types of Concomitant Anti-HIV Drugs | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". Abbreviations for the following terminologies are used to represent results in below table: NRTIs: Nucleoside Reverse Transcriptase Inhibitors, NNRTIs: Non-Nucleoside Reverse Transcriptase Inhibitors. | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Drugs Other Than Anti-HIV Drugs | Participants with adverse drug reactions were assessed in this study. Adverse Drug Reactions are adverse events for which relationship with Lopinavir/Ritonavir tablets is considered as "Related", "Relationship cannot be ruled out", and "Unknown". | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants With Serious Adverse Events | A serious adverse event is an adverse event that 1. requires in patient hospitalization or prolongation of existing hospitalization, 2. results in persistent or significant disability/incapacity, 3. is life-threatening, 4. results in death, 5. is a congenital anomaly/birth defect, or 6. is an important medical event other than the above. | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to 60 Months | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Mean Cluster of Differentiation 4 (CD4) Cell Count in Treatment-Naive Participants at Each Time Point of Observation | | Participants who had both a baseline and at least one post-baseline CD4 cell count value were included in the effectiveness analysis set. | Posted | | Mean | Standard Deviation | cells/mm^3 | | Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Mean CD4 Cell Count in Treatment-Experienced Participants at Each Time Point of Observation | | Participants who had both a baseline and at least one post-baseline CD4 cell count value were included in the effectiveness analysis set. | Posted | | Mean | Standard Deviation | cells/mm^3 | | Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Mean HIV Ribonucleic Acid (RNA) Amount in Treatment-Naive Participants at Each Time Point of Observation | For subjects with plasma HIV-1 RNA quantified as < 400 copies/mL, the result was recorded as 399 copies/mL. | Participants who had both a baseline and at least one post-baseline HIV RNA value were included in the effectiveness analysis set. | Posted | | Mean | Standard Deviation | Log10 copies/mL | | Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Mean HIV RNA Amount in Treatment-Experienced Participants at Each Time Point of Observation | For subjects with plasma HIV-1 RNA quantified as < 400 copies/mL, the result was recorded as 399 copies/mL. | Participants who had both a baseline and at least one post-baseline HIV RNA value were included in the effectiveness analysis set. | Posted | | Mean | Standard Deviation | Log10 copies/mL | | Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Number of Participants in Each CDC Classification Category of HIV-infection Over Time | CDC Categories include Category A: asymptomatic acute phase, Category B: symptomatic other than A or C, and Category C: having an AIDS-indicator disease. | All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period. | Posted | | Number | | participants | | Up to Month 60 after first dose of Lopinavir/Ritonavir | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir: Baseline CDC Category A | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated | | OG001 | Lopinavir/Ritonavir: Baseline CDC Category C | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated | | OG002 | Lopinavir/Ritonavir: Baseline CDC Category Unknown | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
|
| Secondary | Percentage of Participants With Plasma HIV-1 RNA Levels Less Than 400 Copies/Milliliter [mL]) by Duration in Treatment-Naive Participants | Participants whose number of plasma HIV-1 RNA copies was less than 400 copies/mL after the start of treatment were handled as responders. For subjects with plasma HIV-1 RNA quantified as < 400 copies/mL, the result was recorded as 399 copies/mL. | Participants who had both a baseline and at least one post-baseline HIV-1 RNA value were included in the effectiveness analysis set. | Posted | | Number | | percentage of participants | | Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |
| Secondary | Percentage of Participants With Plasma HIV-1 RNA Levels Less Than 400 Copies/Milliliter [mL]) by Duration in Treatment-Experienced Participants | Participants whose number of plasma HIV-1 RNA copies was less than 400 copies/mL after the start of treatment were handled as responders. For subjects with plasma HIV-1 RNA quantified as < 400 copies/mL, the result was recorded as 399 copies/mL. | Participants who had both a baseline and at least one post-baseline HIV-1 RNA value were included in the effectiveness analysis set. | Posted | | Number | | percentage of participants | | Months 0, 3, 6, 9, 12, 24, 36, 48, and 60 after first dosing of Lopinavir/Ritonavir | | | | ID | Title | Description |
|---|
| OG000 | Lopinavir/Ritonavir | Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated |
| |